Forbes Medi-Tech Inc. Comments on Recent Stock Activity

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 08, 2009) - Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) (“Forbes” or the “Company”) today stated that there has been no material change in the Company’s affairs since its last press release. Forbes further stated that there are no material corporate developments that would explain the recent market activity in the Company’s common stock.

Forbes’ last press release was issued on March 30, 2009 and reported on the Company’s financial results for the fiscal year ended December 31, 2008. The Company’s audited financial statements, Management’s Discussion and Analysis, and Annual Report on Form 20-F, each for the fiscal year ended December 31, 2008, have been recently filed with the applicable Canadian and U.S. regulatory authorities and are available to the public at www.sedar.com and www.sec.gov/edgar.shtml.

About Forbes Medi-Tech

Forbes Medi-Tech Inc. (TSX: FMI)(NASDAQ: FMTI) is a life sciences company focused on evidence-based nutritional solutions. A leader in nutraceutical technology, Forbes is a provider of value-added products and cholesterol-lowering ingredients for use in functional foods and dietary supplements. Forbes successfully developed and commercialized its Reducol™ plant sterol blend, which has undergone clinical trials in various matrices and has been shown to lower “LDL” cholesterol levels safely and naturally. Building upon established partnerships with leading retailers and manufacturers across the globe, Forbes helps its customers to develop private label and branded products. For more information about Forbes Medi-Tech, please visit www.forbesmedi.com.

Risks and Uncertainties

Forbes’ business, and any investment in its shares, are subject to a number of risks and uncertainties. The Company has previously stated in its press release dated March 30, 2009 (the “March 30/09 press release”) that management believes the Company’s capital resources are sufficient to finance operations into the fourth quarter of 2009, and that in order to continue operations through and beyond the fourth quarter of 2009, the Company will need to undertake a suitable sale, merger, acquisition or other strategic combination transaction (an “M&A transaction”), or obtain additional financing. While management is considering all financing alternatives, there is no assurance that such funding will be available or obtained on favorable terms. The market for both debt and equity financings for companies such as Forbes has always been challenging. Management is seeking to raise additional funds for operations from potential investors and is also continuing to focus its efforts on obtaining a suitable M&A transaction. The Company’s future operations are completely dependent upon its ability to complete a suitable M&A transaction and/or secure additional funds in the near term, which is not assured. If the Company cannot complete one or more of these, it will have to consider additional strategic alternatives which may include, among other strategies, exploring the monetization of certain intangible assets as well as seeking to out-license assets, potential asset divestitures, winding up, dissolution or liquidation. The above matters raise substantial doubt about the Company’s ability to continue to operate as currently structured.

Additional known risks and uncertainties regarding the Company and its business are contained in the Company’s March 30/09 press release, its MD&A dated March 27, 2009 and its Annual Report on Form 20-F dated March 30, 2009. These documents are publicly accessible at www.sedar.com and www.sec.gov/edgar.shtml.

Reducol™ is a trademark of Forbes Medi-Tech Inc.